Alice Nettleton
Stock Analyst at UBS
(0.67)
# 4,279
Out of 5,189 analysts
19
Total ratings
9.1%
Success rate
-12.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alice Nettleton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Reiterated: Buy | $18 | $9.69 | +85.76% | 2 | Nov 12, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $184 | $121.40 | +51.57% | 3 | Nov 10, 2026 | |
| KARD Kardigan | Reiterated: Buy | $25 | $11.54 | +116.64% | 2 | Nov 9, 2026 | |
| MLYS Mineralys Therapeutics | Rated: Hold | $29 → $19 | $13.66 | +39.09% | 2 | Nov 6, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $27 | $16.96 | +59.20% | 2 | Oct 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Initiated Coverage: Buy | $19 | $8.64 | +119.91% | 1 | Oct 12, 2026 | |
| BIOA BioAge Labs | Initiated Coverage: Hold | $8 | $4.28 | +86.92% | 1 | Oct 11, 2026 | |
| EVMN Evommune | Initiated Coverage: Hold | $8 | $7.04 | +13.64% | 1 | Oct 11, 2026 | |
| NKTR Nektar Therapeutics | Initiated Coverage: Hold | $53 | $30.20 | +75.50% | 1 | Oct 11, 2026 | |
| OCUL Ocular Therapeutix | Initiated Coverage: Buy | $14 | $5.57 | +151.35% | 1 | Oct 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $4.46 | +281.17% | 1 | Oct 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $120 | $93.47 | +28.38% | 1 | Oct 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $26 | $20.73 | +25.42% | 1 | Oct 11, 2026 |
AbCellera Biologics
Nov 12, 2026
Reiterated: Buy
Price Target: $18
Current: $9.69
Upside: +85.76%
Protagonist Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $184
Current: $121.40
Upside: +51.57%
Kardigan
Nov 9, 2026
Reiterated: Buy
Price Target: $25
Current: $11.54
Upside: +116.64%
Mineralys Therapeutics
Nov 6, 2026
Rated: Hold
Price Target: $29 → $19
Current: $13.66
Upside: +39.09%
Odyssey Therapeutics
Oct 20, 2026
Reiterated: Buy
Price Target: $27
Current: $16.96
Upside: +59.20%
Monte Rosa Therapeutics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $8.64
Upside: +119.91%
BioAge Labs
Oct 11, 2026
Initiated Coverage: Hold
Price Target: $8
Current: $4.28
Upside: +86.92%
Evommune
Oct 11, 2026
Initiated Coverage: Hold
Price Target: $8
Current: $7.04
Upside: +13.64%
Nektar Therapeutics
Oct 11, 2026
Initiated Coverage: Hold
Price Target: $53
Current: $30.20
Upside: +75.50%
Ocular Therapeutix
Oct 11, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $5.57
Upside: +151.35%
Oct 11, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $4.46
Upside: +281.17%
Oct 11, 2026
Initiated Coverage: Buy
Price Target: $120
Current: $93.47
Upside: +28.38%
Oct 11, 2026
Initiated Coverage: Hold
Price Target: $26
Current: $20.73
Upside: +25.42%